Interaction Checker

Omalizumab interactions

Omalizumab (Xolair) has 24 documented interactions across the FDA labels and fact sheets we index: 0 major, 24 moderate, 0 minor, and 0 where a label reports no significant interaction. Each entry below quotes the sentence behind it. This drug page is a starting point, not a verdict for your situation.

Interactions from the label

Moderate interactions (24)

  • Azelastine and fluticasoneantihistamineModerate

    Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (Omalizumab label, Warnings and precautions)

  • BeclomethasonecorticosteroidModerate

    Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (Omalizumab label, Warnings and precautions)

  • BetamethasonecorticosteroidModerate

    Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (Omalizumab label, Warnings and precautions)

  • BudesonidecorticosteroidModerate

    Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (Omalizumab label, Warnings and precautions)

  • Budesonide and formoterolcorticosteroidModerate

    Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (Omalizumab label, Warnings and precautions)

  • CiclesonidecorticosteroidModerate

    Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (Omalizumab label, Warnings and precautions)

  • ClobetasolcorticosteroidModerate

    Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (Omalizumab label, Warnings and precautions)

  • DeflazacortcorticosteroidModerate

    Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (Omalizumab label, Warnings and precautions)

  • DesonidecorticosteroidModerate

    Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (Omalizumab label, Warnings and precautions)

  • DexamethasonecorticosteroidModerate

    Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (Omalizumab label, Warnings and precautions)

  • FludrocortisonecorticosteroidModerate

    Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (Omalizumab label, Warnings and precautions)

  • FlunisolidecorticosteroidModerate

    Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (Omalizumab label, Warnings and precautions)

  • FluocinonidecorticosteroidModerate

    Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (Omalizumab label, Warnings and precautions)

  • FluticasonecorticosteroidModerate

    Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (Omalizumab label, Warnings and precautions)

  • Fluticasone and salmeterolcorticosteroidModerate

    Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (Omalizumab label, Warnings and precautions)

  • HalobetasolcorticosteroidModerate

    Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (Omalizumab label, Warnings and precautions)

  • HydrocortisonecorticosteroidModerate

    Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (Omalizumab label, Warnings and precautions)

  • MethylprednisolonecorticosteroidModerate

    Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (Omalizumab label, Warnings and precautions)

  • MometasonecorticosteroidModerate

    Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (Omalizumab label, Warnings and precautions)

  • Olopatadine and mometasoneantihistamineModerate

    Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (Omalizumab label, Warnings and precautions)

  • PrednisolonecorticosteroidModerate

    Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (Omalizumab label, Warnings and precautions)

  • PrednisonecorticosteroidModerate

    Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (Omalizumab label, Warnings and precautions)

  • Tobacco and smokingTobacco and cannabisModerate

    The impact of longer exposure to omalizumab products or use in patients at higher risk for malignancy (e.g., elderly, current smokers) is not known. (Omalizumab label, Warnings and precautions)

  • TriamcinolonecorticosteroidModerate

    Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (Omalizumab label, Warnings and precautions)

Check Omalizumab against everything you take. Add your full list; every pair is checked at once.

Open in the checker

Not medical advice. Severity reflects the label's wording, not your circumstances. A "major" flag can be routine under supervision and a "minor" one can matter at high doses. Ask a pharmacist.